Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Short Interest Down 78.0% in March

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 380 shares, a decline of 78.0% from the March 15th total of 1,725 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 44,767 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Hong Kong Pharma Digital Technology in a research note on Friday, January 9th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Hong Kong Pharma Digital Technology currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. acquired a new stake in shares of Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned 0.39% of Hong Kong Pharma Digital Technology at the end of the most recent reporting period.

Hong Kong Pharma Digital Technology Trading Up 5.5%

Shares of NASDAQ:HKPD traded up $0.03 on Monday, hitting $0.66. The company’s stock had a trading volume of 12,745 shares, compared to its average volume of 38,443. The company has a current ratio of 2.93, a quick ratio of 2.73 and a debt-to-equity ratio of 0.28. Hong Kong Pharma Digital Technology has a 12 month low of $0.37 and a 12 month high of $2.76. The stock’s 50-day moving average is $0.67 and its two-hundred day moving average is $0.89.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last issued its quarterly earnings data on Wednesday, March 18th. The company reported $0.01 earnings per share for the quarter. The company had revenue of $3.57 million for the quarter.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.